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Abstract: The aim was to explore the body of literature focusing on protective treatments against
endothelial glycocalyx degradation in surgery. A comprehensive systematic review of relevant articles
was conducted across databases. Inclusion criteria: (1) treatments for the protection of the endothelial
glycocalyx in surgery; (2) syndecan-1 used as a biomarker for endothelial glycocalyx degradation.
Outcomes analysed: (1) mean difference of syndecan-1 (2) correlation between glycocalyx degradation
and inflammation; (3) correlation between glycocalyx degradation and extravasation. A meta-
analysis was used to present mean differences and 95% confidence intervals. Seven articles with eight
randomised controlled trials were included. The greatest change from baseline values in syndecan-1
concentrations was generally from the first timepoint measured post-operatively. Interventions
looked to either dampen the inflammatory response or fluid therapy. Methylprednisolone had
the highest mean difference in plasma syndecan-1 concentrations. Ulinastatin showed correlations
between alleviation of degradation and preserving vascular permeability. In this systematic review of
385 patients, those treated were more likely than those treated with placebo to exhibit less shedding
of the endothelial glycocalyx. Methylprednisolone has been shown to specifically target the transient
increase of glycocalyx degradation immediately post-operation and has displayed anti-inflammatory
effects. We have proposed suggestions for improved uniformity and enhanced confidence for future
randomised controlled trials.
Keywords: endothelial glycocalyx; inflammatory response; fluid loading; surgery; post-operative;
albumin extravasation
1. Introduction
The vascular endothelium plays several important roles including haemostatic balance,
endothelial integrity, and blood flow regulation [1]. It comprises a single layer of endothelial
cells, lining every blood vessel in the body and is understood to be 4000–7000 m2 [2]. These
cells play a vital role as a semipermeable membrane to allow the exchange of nutrients
and the removal of waste to and from the blood. A key structure involved in these actions
is the endothelial glycocalyx (EG), which coats cells’ extracellular matrix. EG thickness
ranges from 0.2 µm in capillaries to 4.5 µm in the carotid artery [3]. The glycocalyx enables
changes by a process known as mechanotransduction.
Mechanotransduction is the mechanism by which external mechanical stimuli are
converted into cellular responses through signalling pathways [4]. The apical surface of
the glycocalyx consists of glycosaminoglycans (GAGs); those commonly associated with
the vasculature are heparan sulphate (HS), chondroitin sulphate (CS) and hyaluronic acid
(HA) [5]. Additionally present are syndecans, which provide sites on the apical surface to
highly regulate proteolytic cleavage. The best conceptual theory for glycocalyx to detect
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changes in blood flow was described by Squire [6] as the “wind in the trees”. The wind
(fluid flow) is sensed by the branches (GAGs) of which the drag force is transmitted through
the trees/forest (glycocalyx) and stimulates a response. Twenty-four-hour exposure of
fluid shear-stress (FSS) in an in vitro model of EG has been shown to enhance synthesis
and distribution of the prevalent components (HS, CS, and HA) of the glycocalyx with
nearly normal uniform spatial distribution, similar to baseline levels compared to only
30 min of exposure [7].
Surgery is associated with EG degradation [8]. A suggested mechanism for this
is that the thickness of the glycocalyx, and thus the surface layer, is reduced by is-
chaemia/reperfusion [9]. This increases capillary permeability and, thereby, contributes to
tissue oedema (Figure 1) [10]. EG degradation is known to disrupt the equilibrium between
pro-inflammatory cytokines and adhesion molecules, and vasodilators and vasoconstric-
tors, leading to endothelial dysfunction [11]. Glycocalyx components are released, such as
syndecan-1 and heparan sulphate, during surgery. However, the steps in which diseases,
trauma, and surgery thin the EG are not well understood. Johansson et al. [12] undertook
a prospective 75-patient double-blind cohort study and found trauma patients to have
raised plasma syndecan-1 levels associated with 16 other markers for inflammation, and
tissue and endothelial cell damage. Patients with significant EG degradation were shown
to have a three-fold increase in mortality compared to those with lower syndecan-1 levels.
A mechanism to explain the strong association between EG degradation and patients with
trauma is through the extensive activation of the inflammatory and coagulation pathways.
Protection against EG degradation could help treat against known diseases to shed major
EG constituents, such as diabetes and hyperglycaemia, atherosclerosis and chronic kidney
disease [13].
Figure 1. EG structure during health (left) and degradation (right). Disease causes thinning of the glycocalyx. Glycocalyx
constituents are released into the plasma. An inflammatory response is produced with the recruitment of leucocytes and the
loss of fluid.
Recent studies have looked into pharmacological interventions to prevent EG degra-
dation during surgery. With the limited studies, interventions have looked into two
therapeutic routes: (1) dampening the inflammatory response and (2) fluid-therapy. (1)
The EG plays an important role in the post-injury inflammatory response [14]. An increase
in C-reactive protein (CRP) has been associated with a decreased thickness of the EG and
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impaired vasoreactivity [15]. (2) Infused fluid therapy has been associated with impaired
microcirculation, resulting in tissue oedema. Moreover, fluid infusion could cause EG
degradation and further fluid loss into the lymphatic system through albumin and other
plasma proteins moving across the vascular wall [16].
This systematic review and meta-analysis looks to examine the body of literature into
protective treatments for EG degradation in surgery from most of the published clinical
trials. The aim is to identify trends in treatments which may address the mechanism for
which surgery causes EG degradation.
2. Materials and Methods
2.1. Search Strategy
A comprehensive review of the literature was conducted in May 2020, using databases,
such as Cochrane Library of Systematic Reviews, Cochrane Central Register of Clinical
Trials (CENTRAL), MEDLINE, PubMed, and Clinical Trials.org. Article selection was
limited to publications in the English Language between 1 January 1950 and 20 May
2020. Search terms used were a combination of the following: “endothelial”, “glycocalyx”,
and “degradation”. Reference lists of the selected articles and other related studies were
assessed for eligibility. Cross-referencing from identified articles and conference abstracts
were also performed. Clinical trials which are currently in progress with no data available
were not included.
2.2. Inclusion Criteria
One researcher (H.K.) performed the review process for inclusion in the systematic
review. Specific inclusion criteria mandated systematic reviews and clinical trials that were
from retrospective or prospective investigations which met the following criteria; (1) papers
published in the English Language; (2) clinical investigations into protective treatments for
EG; (3) syndecan-1 used as a biomarker for EG degradation (specific marker for significant
degradation as opposed to HS for minor disturbances); (4) clinical investigations in which
patients were followed from pre-operative/induction of anaesthesia to the end of surgical
treatment [17].
2.3. Exclusion Criteria
From the search strategy, 987 studies were selected. The first screen excluded articles
if they had not conducted investigations on surgical patients. A further screen excluded
articles that investigated combined treatments and those in which more than one substance
was administered during surgery.
After exclusion, 112 articles formed the inclusion of the initial review. Following this,
an independent abstract review was conducted by the same author for the title review.
Three were removed as they investigated the role of the EG within surgery without the use
of an intervention. One assessed the microperfusion abilities of endothelial cells following
surgery. Twenty-nine articles investigated the effects of surgery (cardiothoracic, abdominal,
hysterectomy, etc.) on the EG and whether surgery is a stimulatory factor for EG degrada-
tion. Twelve articles looked into protective biological factors and signalling pathways of
the body that are used to protect against EG degradation in surgery. Twenty-one articles
were trials conducted on animals/in-vitro models. Twenty-nine articles investigated the
effects of different surgical procedures had on the structural integrity of the EG. Six articles
were related to the effects that degradation of the EG had on other systems.
The final screen of 11 articles in their entirety was completed by the same researcher
(Khan, H) to ensure adequate data content for inclusion in the systematic review. One
had been centred on post-operative interventions which focuses more into regenera-
tion/recovery of the EG [18]. Three articles were excluded as they were clinical trials
still undergoing with no preliminary results [19–21].
After the full text review, the final search included 7 articles that met the inclusion
criteria and thus were used for analysis and data were extracted (Brettner et al. [22];
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Kim et al. [23]; Lindberg-Larsen et al. [24]; Mennander et al. [25]; Nemme et al. [26];
Pesonen et al. [27]; Wang et al. [28]). The search strategy has been depicted in Figure 2.
Figure 2. PRISMA flow chart of search strategy to identify pivotal publications of protective treatments against EG
degradation in surgery for meta-analysis.
2.4. Data Extraction
Data were extracted and then reviewed, and all reported results were summarised to
include comparable and clinically relevant outcomes. The following data were extracted
from each clinical trial and used for descriptive comparison; author, year, study design,
sample size, surgery, type of treatment, time points for administration of treatment (and/or
placebo), biomarkers used to measure endothelial cell glycocalyx degradation, time points
used for biomarker measurements (Table 1), and details regarding degree of endothelial
cell glycocalyx degradation and post-surgical complications (Table 2).
2.5. Statistical Analyses
Using GraphPad Prism version 8, a line graph was produced to assess the change
in plasma syndecan-1 concentrations in the control groups of the included articles. This
enabled identification of the timepoints at which to expect interventions to target. This
analysis formed the basis of a forest plot. Some articles provided checkpoints in surgery
for when blood samples were taken rather than averaged time-points of each sample. The
provided averaged times for each stage in surgery were converted to averaged timepoints
when blood samples were taken. Meta-analysis was conducted using RevMan 5.4 from
Cochrane Review to derive pooled effect estimates as a mean difference associated with 95%
confidence intervals. The effect on the analysis of within and between study heterogeneity
was quantified by calculating I2. Overall, 4 studies with 5 randomised controlled trials
were included for the forest plot.
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Table 2. Outcome on EG degradation.
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Table 2. Cont.
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3. Results
3.1. Description of Included Studies
The articles included were published in 2012–2019. Sample sizes varied from 16 pa-
tients [25] to 120 patients [23]. From the remaining 6 articles, patients’ median age ranged
from 7 months [27] to 67.8 years-old [21]. One article did not provide any informa-
tion for patient average age [25]. Four articles did not include a range for the patients’
ages [23,24,27,28] but a standard deviation. From the remaining 2 articles that included
patient’s age range, the range was from 1 month to 72 years-old.
Two articles described two treatments using different sample groups with no control
group [23,25]. The remaining 5 articles investigated their treatment using two patient
groups (control vs. intervention). One article conducted two separate randomised, prospec-
tive clinical trials by testing the intervention on two different patient cohorts based on
age and surgical procedure [27]. All articles had delivered their drug following the ad-
ministration of anaesthesia. Of the articles to investigate protective interventions for EG
degradation, 4 looked into CPB [22–24,26], 1 into abdominal hysterectomy [26], 1 in knee
replacement surgery [24] and 1 in pulmonary lobe resection [28].
3.2. Outcomes and Results
When analysing the included articles of our systematic review, the focus was on (1) the
comparison between control and intervention groups to reduce levels of EG degradation
in surgery; (2) correlations between glycocalyx degradation and an inflammatory response;
and (3) correlation between glycocalyx degradation and extravasation. For each study, we
assessed biomarkers for glycocalyx degradation (syndecan-1, and those that measured HS),
as well as those that measured inflammatory markers and capillary leakage.
Four studies investigated the protective treatments against degradation of the EG
in CPB [22,23,25,27]. Only 2 studies [25,27] showed a significant lowering of plasma
syndecan-1, which in both cases occurred during surgery. The Mennander [25] study,
which investigated the effects of diazoxide, found similar changes in hyaluronan (p < 0.04
and p < 0.04 respectively). The Brettner study [22] investigated the effects of hydro-
cortisone. There were no significant differences in plasma syndecan-1 levels between
intervention and control groups. However, they did establish significant lowering of
HS levels intra-operatively. The Kim study [23] differed from the other clinical trials by
comparing two interventions; hydroxyl starch (HES) vs. crystalloid. It has also differed
from the other studies as patients had undergone off-pump CPB, which is of clinical sig-
nificance as studies have shown differences in plasma syndecan-1 and plasma heparan
sulphate concentrations between surgeries [29]. Following infusion of 20 mL/kg of the
study fluids, median syndecan-1 levels were higher in the HES group than the crystalloid
group [(79.7 (46.6–176.6) vs. 62.7 (30.1–103)]. However, overall peri-operative changes in
syndecan-1 were not significantly different between the groups.
Of the 4 selected articles, the Brettner study [22] was the only to investigate the
inflammatory response in addition to glycocalyx degradation. There was significant
lowering of CRP levels on days 1, 2 and 3 post-operatively in the hydrocortisone group (p
is 0.014, 0.012 and 0.022 respectively). Interleukin-6 (IL-6) was significantly lower in the
intervention group to the control group (p < 0.05).
One study [27] used urinary trypsin inhibitor (UTI) to treat EG degradation in video-
assisted thoracoscopy (VATS) lobectomy. There were no significant differences in baseline
values of syndecan-1, HS, HGB and serum albumin levels in the control and UTI group.
However, syndecan-1 levels were elevated at T1 in the control group (3.77 ± 3.15 versus
4.28 ± 3.30, p = 0.022), whereas the UTI group showed no significant increase at T1
(3.98 ± 3.04 versus 4.24 ± 3.12, p = 0.160). There were no obvious changes in HS levels
between groups.
One study looked into the effects of pre-operative methylprednisolone treatment in
total knee arthroplasty [24]. Syndecan-1 concentrations remained stable in the control
group with a statistically significant drop from baseline to 24-h post-operative (14.1 ± 1.4
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versus 12.4 ± 12.4, p = 0.001). Vascular endothelial growth factor (VEGF) increased in both
groups with only a transient increase in the methylprednisolone group (T0->T6: 42.4 (2.5) to
54.8 (4.1), p = 0.008 versus 37.7 (2.5) to 47.7 (4.9), p = 0.019). Soluble thrombomodulin (sTE)
increased in both groups but only transiently in the methylprednisolone group (T0->T6:
5.0 (0.2) to 5.4 (0.3), p = 0.008 versus 5.0 (0.2) to 5.2 (0.4), p = 0.022). CRP increased in
both groups but less so in the methylprednisolone group (T0->T24: 4.5 (1.1) to 36.6 (3.6)
versus 6.9 (2.2) to 74.4 (5.0)). Overall, effects of methylprednisolone were more pronounced
at higher base values in sTM, sE-Selectin and VEGF (p =0.012, p = 0.009 and p < 0.001,
respectively) but this was not the case for syndecan-1.
One study looked into the effects of ringer’s lactate (a form of fluid therapy) to prevent
EG degradation in abdominal hysterectomy [26]. This article differs from other included
studies, as the two groups were based on different anaesthetic medications (propofol or
sevoflurane), with no control group. Plasma syndecan-1 and HS levels showed minimal
variations during surgery but significantly increased 2-h post-operatively (p < 0.05 and
p < 0.001, respectively, between 90 min and 2 h, compared using Wilcoxon’s matched-pair
test). Plasma concentrations for brain natriuretic peptide (BNP) showed small changes but
no significant differences between groups.
There was a common significant increase in plasma syndecan-1 concentrations be-
tween baseline values and the first time-point post-operation. Data from the articles plotted
(Figure 3) showed similar baseline values compared with their corresponding intervention
group. Hence, we used the first timepoint post-operation from each article as the basis
for the forest plot (Figure 4). Patients receiving diazoxide in CPB, methylprednisolone
in CPB for neonates, methylprednisolone in VSD trial, methylprednisolone in total-knee
arthroplasty, UTI in VATS lobectomy, had pooled mean differences of −1.4 (95% CI: −3.67,
0.87), −83.1 (95% CI: −150.4, −15.8), −59.0 (95% CI: −96.97, −21.03), −10 (95% CI: −20.79,
0.79) and −0.1 (95% CI: −9.0, −9.80), respectively.
Figure 3. Changes in plasma syndecan-1 concentration in the control groups of the included articles. Values lower than
x = 0 represent blood samples taken pre-operative. Values within the grey region are samples recorded intra-operatively.
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Figure 4. Forest plot of the mean difference of plasma syndecan-1 concentration changes for treatments to protect against EG degradation in surgery.
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4. Discussion
To the authors’ knowledge, there has been no systematic review to investigate treat-
ments to protect against EG degradation in surgery. In our study, the greatest change
in plasma syndecan-1 concentrations from baseline values, was generally found at the
first timepoint measured post-operatively. Syndecan-1 is a marker for greater trauma of
EG shedding, so more time may be required for this extent of damage to occur and to
be detected. The transient increase can be explained by the proteolytic degradation of
the glycocalyx with subsequent rapid clearance, especially via the kidneys [30]. A slow
systemic degradation could be explained by a general activation of leucocytes and platelets
with an associated release of enzymes that shed the glycocalyx [31]
Pooled data from 196 patients in 5 randomised controlled trials for protective treat-
ments against EG degradation in surgery indicated that patients treated with experimental
drugs were more likely to respond than those treated with placebo, with a pooled mean
difference of −8.94 (95% CI: −19.60, 1.61). Randomised controlled trials using methylpred-
nisolone were shown to have the greatest effect to inhibit elevation of syndecan-1 levels.
This may be important as it provides evidence for the development of personalised inter-
ventions, targeting patients in selected groups with altered risk profiles, for example, using
bolus I.V. methylprednisolone in patients with high baseline values of endothelial activa-
tion and damage. Lindberg-Larsen study [24] found that the effect of methylprednisolone
on syndecan-1, sTM and VEGF concentrations was dependant on the time of sampling,
with these outcomes increasing with time. Pesonen study [27] showed similar changes in
which methylprednisolone failed to inhibit the increase of syndecan-1 shedding at the early
time-points, yet showed significant lowering of syndecan-1 levels to its corresponding
control group for later time-points. A combination of the previous work on interleukins by
Keski-Nisula [32] and these present syndecan-1 results suggest that methylprednisolone
probably mediates the conservation of glycocalyx by an anti-inflammatory action. This is
operative at the time-points when interleukin production is regulated via de novo protein
synthesis due to glucocorticoid receptor activation. Of the three randomised clinical trials,
with only one of them to have their upper-confidence interval to go beyond the line of no
effect by 0.79 ng/mL, future work on methylprednisolone could be promising to protect
the EG in surgery.
Brettner [22] showed hydrocortisone to reduce minor disturbances and not significant
degradation of the EG. This shows that mechanistic pathways involved with shedding of
heparan sulphate side-chains evoked by the combined stimuli of surgery were more suscep-
tible to inhibition by hydrocortisone than the one leading to cleavage of the transmembrane
core protein, syndecan-1. Whilst inflammatory markers (IL-6 and CRP) had shown signifi-
cantly higher levels in the control group to the hydrocortisone group post-operatively, it
had no relevant influence on inflammatory clinical parameters. As highlighted previously,
the Lindberg-Larsen study [24] showed the effect of methylprednisolone on syndecan-1,
sTM and VEGF concentrations was dependant on the time of sampling, with these out-
comes increasing with time. However, this study showed no correlation with changes in
CRP and any of the EG degradation markers. Analysis of the Nemme study [26] was chal-
lenging with no control group, however, there were no marked changes in BNP, syndecan-1,
heparan sulphate and CRP between the two groups. There was no correlation between
inflammatory markers (BNP and CRP) and glycocalyx shedding products.
The following results from the three articles differed from their previous research.
Experimental studies had shown hydrocortisone to provide EG protective properties, most
probably due to the stabilisation of mast cells, and, therefore, the amelioration of histamine,
cytokines, lysases and protease production [9,33,34]. Stress doses of hydrocortisone ad-
ministered before cardiac surgery in high risk patients attenuated systemic inflammation
and improved early outcomes [35]. Glucocorticoids, such as methylprednisolone, have
been shown in animal studies to reduce oedema formation and shedding of the glycocalyx
by reducing the systemic inflammatory response in surgery [36]. Nemme [26] was unable
to replicate the typical acute increase in BNPs seen previously experimentally [37,38] and
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post-operatively [39]. The included articles did not investigate the association between the
degradation of the EG and cytokine production. Further surgical studies should look to
understand the association and mechanism between EG shedding and cytokines’ influence
on endothelial permeability.
A common problem found in each randomised controlled trial was minimal shedding.
The two reasons in which minimal shedding could have occurred are (1) the small patient
sample and (2) the low operative stress in each clinical trial. Johansson study [12] showed
that patients undergoing surgery from significant trauma had elevated syndecan-1 concen-
trations associated with raised inflammatory markers. This could highlight that significant
EG degradation is needed to stimulate an inflammatory response, and hence, allow the
action of anti-inflammatory medication to protect and treat against the symptoms.
Wang et al. [28] found a significantly greater decrease in plasma albumin compared
with HGB at POD1, suggesting that serum albumin was not only lost as a result of blood
loss but also by extravasation and attributed this to increased vascular permeability. Fur-
thermore, serum albumin levels were significantly lower at POD1 in the control group
compared to the UTI group, yet HGB levels were similar in both groups. This suggests that
serum albumin leakage was reduced as a result of a decrease in microvascular permeability
in the UTI group. With the UTI group showing no significant increase in syndecan-1,
not only does this provide evidence of association between alleviation of degradation
and preserving vascular permeability, it also suggests the development of personalised
interventions against oedema formation as a result of surgery. With these findings, it
may suggest a mechanism whereby UTI acts to protects the vascular endothelial barrier
function during surgery, and therefore reduce tissue oedema. The Nemme study [26], also
used the latter approach to investigate fluid maintenance in surgery to protect against EG
degradation. A comparison between variables could only be made from the first hour
post-infusion, which suggested intravascular albumin leakage out of the bloodstream at a
normal rate. However, the data did not support previous work that suggested significant
capillary leakage of albumin in response to hypervolemia [40].
Whilst this analysis provides useful information for clinicians for future work, the
following limitations should be noted. As with all meta-analyses, the precision of pooled
effect estimates is dependent on the sample size. Therefore, of all the included articles
which had small sample sizes, greater patient cohorts are needed to be truly representative
of the clinical outcomes experienced in the population. We have seen the contradictory
evidence of EG degradation in surgery, yet it is well-understood that greater operative-
stress does have an impact on endothelial integrity. Where there was a lack of ability
to disrupt EG structure, this produced varying degrees of inflammatory responses and
albumin leakage. Correlation between EG degradation and inflammatory markers as well
as pronounced extravasation were difficult to analyse. Included articles did not investigate
the source of EG degradation products produced during surgical operations. Overall, the
included trials showed no significant difference in clinical signs and symptoms between
intervention and control groups, differing to the work of Johansson et al. [12].
Despite the relative similarity of the study design of the randomised controlled trials
(RCTs) included in the systematic review, there are always some levels of inconsistency due
to variability in factors, such as treatment duration, outcomes assessed, patient age, severity
of illness for need of surgery and co-morbid conditions. This is of clinical significance
as plasma concentration of syndecan-1 and hyaluronic acid can vary dependant on the
kidney’s ability to excrete them [41]. These facts have not been reported consistently and
cannot be assessed in this study. Finally, the authors were unable to find universal dosing
strategies identified from official bodies for guidelines to treat EG degradation in surgery.
Therefore, the dosing strategies in the RCTs were variable.
With the relatively-high level of heterogeneity indicated by I2, these limitations high-
light a real need for a set design for clinical trials to cohesively investigate protective
treatments against EG degradation in surgery. Guidelines and reporting standards should
be used to increase uniformity and reduced heterogeneity between RCTs, therefore max-
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imising confidence, validity and comparative analysis for subsequent systematic reviews.
Following is a list of suggestions for future RCTs on this topic;
• Study design: trials should be a placebo-controlled, double-blind, and a parallel design,
with treatment administered pre-operatively or following the induction of anaesthesia
but before the start of the surgical procedure. Time-points should be assessed at all
stages of the surgical operation (pre-operative, intra-operative and post-operative) to
assess trends in which the treatments affect the production of glycocalyx products.
• Patient population: RCTs should evaluate the work of Johansson study [12] to assess
EG degradation in patients with greater operative stress. Mean age, concomitant
medication, incidence and common co-morbidities should be collected and reported
for each treatment group.
• Clinical outcomes: syndecan-1 and heparan sulphate should be used as primary
markers to measure the degree of EG degradation. In addition, inflammatory markers
(CRP, white blood cells) as well as capillary leakage of albumin (HGB and albumin)
should be measured and correlated to identify relationships with glycocalyx shedding.
Future work should use either Hedin and Hahn [42] or Hasselgren [43] technique to
measure capillary leakage.
5. Conclusions
Whilst the effects of surgery are known to cause shedding of the EG, clinical surgical
research into protective treatments for this structure are still in the early stages. The aim of
this systematic review was to investigate treatments listed on large clinical databases to
protect against EG degradation in surgery. Reviewing the pooled data from 385 patients
in 8 RCTs, interventions looked to target (1) dampening the inflammatory response or (2)
fluid maintenance during surgery. From these initial studies, we have seen some promising
results. Methylprednisolone is shown to target the transient increase of syndecan-1 levels
immediately after surgery. There is evidence that UTI can reduce the degradation of the EG
with a reduction of albumin extravasation. Building from the initial findings of the included
studies in this systematic review, and following the proposed suggestions for study design,
the hope is that future RCTs will improve uniformity and maximise confidence for finding
protective treatments for the EG in surgery.
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